Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 9/20 | 0.53 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.43 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.43 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.43 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.43 |
| ▸ | ACE | P12821 | 1/20 | 0.43 |
| ▸ | MMEL1 | Q495T6 | 1/20 | 0.42 |
| ▸ | CCKBR | P32239 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.41 |
| ▸ | KLK7 | P49862 | 1/20 | 0.40 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.40 |
| ▸ | CTSS | P25774 | 1/20 | 0.40 |
| ▸ | UGCG | Q16739 | 1/20 | 0.39 |
| ▸ | TACR1 | P25103 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1375660 | 1.00 | S1PR1 (0.53) | S1PR1ADORA3ADORA2AADORA2BADORA1 | |
| SCHEMBL1375663 | 1.00 | S1PR1 (0.53) | S1PR1ADORA3ADORA2AADORA2BADORA1 | |
| SCHEMBL9983998 | 0.90 | S1PR1 (0.58) | S1PR1MMEL1CCKBRMEN1HPGD | |
| SCHEMBL9984002 | 0.90 | S1PR1 (0.58) | S1PR1MMEL1CCKBRMEN1HPGD | |
| SCHEMBL27840861 | 0.87 | S1PR1 (0.58) | S1PR1CCKBRMEN1HPGDKMT2A | |
| SCHEMBL1373220 | 0.87 | S1PR1 (0.58) | S1PR1CCKBRMEN1HPGDKMT2A | |
| SCHEMBL1372968 | 0.85 | S1PR1 (0.57) | S1PR1CCKBRMEN1HPGDKMT2A | |
| SCHEMBL12044791 | 0.83 | S1PR1 (0.55) | S1PR1CCKBRPABPC1KLK7KLK5 | |
| SCHEMBL1371682 | 0.83 | S1PR1 (0.56) | S1PR1CCKBRMEN1HPGDKMT2A | |
| SCHEMBL27840733 | 0.83 | S1PR1 (0.56) | S1PR1CCKBRMEN1HPGDKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8802692-B2 | Synergistic effects between sphingosine-1-phosphate receptor antagonists and antimicrotubule agents | EXELIXIS, INC. (US) | 2014-08-12 | — | — | US | claimed |
| US-8791102-B2 | Acetanilide sphingosine-1-phosphate receptor antagonists | EXELIXIS, INC. (US) | 2014-07-29 | — | — | US | disclosed |
| US-20110288076-A1 | Sphingosine-1-Phosphate Receptor Antagonists | EXELIXIS, INC. (US) | 2011-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110288076-A1 | Sphingosine-1-Phosphate Receptor Antagonists | S1PR1, S1PR2, S1PR3 | S1PR1 1/4885ADORA3 423/4885ADORA2A 154/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.